Duality of Interest. K.R.T. is supported by National Institutes of Health research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, and UM1AI109568 and Centers for Disease Control and Prevention project number 75D301-21-P-12254. She has also received investigator-initiated grant support from Travere and Bayer Pharmaceuticals outside of the submitted work. K.R.T. reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, and Travere. I.P., A.Ha., R.T., R.J.W., and A.He. are employees and shareholders of Eli Lilly and Company. D.Z.I.C. has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometic, Bristol-Myers Squibb, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, and Novo Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo Nordisk. N.S. recognizes grant support from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics; has received consulting fees from Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Hanmi Pharmaceuticals, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; and has received payment for lectures or manuscript writing from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, and Novo Nordisk. H.J.L.H. acts as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, CSL-Behring, Eli Lilly and Company, Gilead, Janssen, Novartis, Novo Nordisk, and Travere and received research support from AbbVie, AstraZeneca, Boehringer Ingelheim, Janssen, and Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.
PubMed
